Clinical trials: Prostatectomy
Cancer Of Prostate, Prostate Neoplasms
Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
Background: Sometimes prostate cancer comes back after a person's prostate is removed. In this case, radiation is a common treatment. Radiation kills prostate cancer cells. It can be very effective.
- Conditions
- Cancer Of Prostate, Prostate Neoplasms, Prostate Cancer, Neoplasms of Prostate
- Trial name
- NCT03388619
- Testing
- Prostate bed with integrated boost, Prostate bed irradiation only, Whole Body Bone Scan
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoceles Following Pelvic Lymph Node Dissection
Cold Plasma for the Reduction of Lymphoceles Following PLND
This study protocol will evaluate the efficacy of Bovie Medical's J-Plasma® helium based plasma technology in the reduction of lymphoceles following pelvic lymph node dissection (PLND) during robotic assisted radical…
- Trial name
- NCT02658851
- Testing
- J-Plasma
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Apyx Medical
Prostate Adenocarcinoma, Stage I Prostate Adenocarcinoma AJCC v7
Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer
This randomized phase III trial studies how well hypofractionated radiation therapy works compared to conventional radiation therapy after surgery in treating patients with prostate cancer.
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
- Trial name
- NCT03274687
- Testing
- Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- 241 sites in United States, Canada and 1 more
- Volunteers
- 296 people
- Sponsor
- NRG Oncology
Prostate Cancer
FACBC Outcomes for Post Prostatectomy
Investigators will perform a study with 162 patients in whom there is a strong suspicion of prostate cancer that has returned to the body after having a prostatectomy.
- Trial name
- NCT01666808
- Testing
- FACBC, Radiation therapy
- Where
- United States
- Volunteers
- 165 people
- Sponsor
- Emory University
Prostate Adenocarcinoma
Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes
This phase II trial studies how well a positron emission tomography (PET)/computed tomography (CT) scan using fluciclovine F18 compared with a PET/CT scan with 68Ga-PSMA works in planning radiation treatments and enhancing…
- Trial name
- NCT03762759
- Testing
- Computed Tomography, Fluciclovine F18, Gallium Ga68-labeled PSMA-11
- Where
- 3 sites in United States
- Volunteers
- 140 people
- Sponsor
- Emory University
Prostate Cancer
Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer
The purpose of this study is to determine if enzalutamide is an effective therapy in treating localized prostate cancer prior to prostatectomy.
- Trial name
- NCT01547299
- Testing
- Enzalutamide, Leuprolide, Dutasteride
- Where
- 4 sites in United States, Canada
- Volunteers
- 52 people
- Sponsor
- Pfizer
Postsurgical Pain, Analgesia
TAP-patients With Robotic Assisted Lap Prostatectomy
The purpose of the study is to assess the safety and efficacy of EXPAREL when administered via infiltration into the transversus abdominis plane (TAP) to prolonged postsurgical analgesia in men undergoing robot-assisted…
- Conditions
- Postsurgical Pain, Analgesia, Prostatectomy
- Trial name
- TAP (NCT01582477)
- Testing
- EXPAREL 20 mL, EXPAREL 40 mL
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Stage I Prostate Adenocarcinoma American Joint Committee on Cancer (AJCC) v7, Stage II Prostate Adenocarcinoma AJCC v7
Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
This phase I trial studies stereotactic body radiation therapy (SBRT) in treating patients with prostate cancer that is likely to come back or spread (high-risk) undergoing surgery.
- Conditions
- Stage I Prostate Adenocarcinoma American Joint Committee on Cancer (AJCC) v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
- Trial name
- NCT02830165
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Penile Cancer, Erectile Dysfunction
Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy
When a bilateral nerve-sparing radical prostatectomy (RP) is performed, recovery of erectile function (rigid erections) is reported for up to 80% of patients, who are less than 60 years old.
- Conditions
- Penile Cancer, Erectile Dysfunction, Radical Prostatectomy
- Trial name
- NCT00955929
- Testing
- Sildenafil and questionnaire, Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostatectomy
Intra-operative Assessment of Cavernosal Nerve Stimulus Threshold
Erectile dysfunction persists in approximately 80% of men 1 year after prostatectomy. Various erectile rehabilitation strategies have not provided benefit.
- Trial name
- NCT03150758
- Testing
- 10Hz + 100 micro-seconds, 10Hz + 200 micro-seconds, 7Hz + 100 micro-seconds
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Case Comprehensive Cancer Center
Erectile Dysfunction
Research Evaluating an Investigational Medication for Erectile Dysfunction - Post-Prostatectomy
The objectives of this study are to evaluate the safety and efficacy of two doses of avanafil in the treatment of adult males for erectile dysfunction following bilateral nerve-sparing radical prostatectomy.
- Trial name
- NCT00895011
- Testing
- Avanafil
- Where
- 51 sites in United States
- Volunteers
- 298 people
- Sponsor
- VIVUS LLC
Adenocarcinoma of the Prostate
Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy
This pilot study aims to investigate the diagnostic utility of 18F-DCFPyL, a novel low-molecular weight PSMA PET/CT imaging agent, in men with an elevated PSA following radical prostatectomy.
- Trial name
- NCT02523924
- Testing
- 18F-DCFPyL
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Use of Hypothermia During Robotic Prostatectomy
Robotic assisted laparoscopic radical prostatectomy (RLP) has gained widespread acceptance as a standard treatment for clinically localized prostate cancer.
- Trial name
- NCT00915031
- Testing
- UroCool
- Where
- United States
- Volunteers
- 738 people
- Sponsor
- University of California, Irvine
Prostate Cancer
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma
VA Cooperative Study #553 is designed to prospectively evaluate the efficacy of early adjuvant chemotherapy using docetaxel and prednisone added to the standard of care for patients who are potentially cured by radical…
- Trial name
- CAP (NCT00132301)
- Testing
- Docetaxel, Prednisone
- Where
- 34 sites in United States, Puerto Rico
- Volunteers
- 298 people
- Sponsor
- VA Office of Research and Development
Prostate Cancer
Global Performance Evaluation of the AMS CONTINUUM™ Device
1. To evaluate Device performance in providing mucosa to mucosa apposition to facilitate sustainable vesico-urethral anastomosis during a radical prostatectomy procedure. 2.
- Trial name
- NCT01083199
- Testing
- CONTINUUM™
- Where
- 2 sites in Greece, Spain
- Volunteers
- 10 people
- Sponsor
- American Medical Systems
Prostate Cancer
Effects of IAS in Men With Localized Biochemical Relapsed Prostate Cancer
This study was a prospective analysis in men with localized prostate cancer who had rising Prostate Specific Antigen (PSA) levels after definitive treatment with surgery or radiation.
- Trial name
- IAS (NCT00223665)
- Testing
- Flutamide, Leuprolide Acetate
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- University of Washington
Prostate Cancer
A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery
Patients with post-prostatectomy PSA (Prostate Specific Antigen) recurrences with aggressive disease features will receive salvage radiation therapy and standard androgen deprivation therapy (ADT) or enhanced ADT to determine if…
- Trial name
- STEEL (NCT03809000)
- Testing
- Radiation Therapy, Enzalutamide, Bicalutamide
- Where
- 108 sites in United States, Canada
- Volunteers
- 188 people
- Sponsor
- RTOG Foundation, Inc.
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8
Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy
This phase II trial studies how well apalutamide works in treating patients with prostate cancer before radical prostatectomy. Androgen can cause the growth of prostate cancer cells.
- Trial name
- NCT03412396
- Testing
- Apalutamide, Quality-of-Life Assessment, Radical Prostatectomy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Salvage Radiation Therapy and Taxotere for PSA Failure After Radical Prostatectomy
The main purpose of this study is to try to find out whether adding chemotherapy to the standard treatment for your stage of prostate cancer is more effective than the standard treatment by itself.
- Trial name
- NCT00480857
- Testing
- Docetaxel (Taxotere)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Michigan Rogel Cancer Center
Prostatic Neoplasms
Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer
This is a multicentered, open label, randomized phase II trial of PROSTVAC or ipilimumab or the combination of PROSTVAC and ipilimumab as neoadjuvant therapy in patients with localized prostate cancer.
- Trial name
- NCT02506114
- Testing
- PROSTVAC V/F, Ipilimumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Lawrence Fong